文献速递妇科

Elagolix联合反向添加疗法治疗子宫肌瘤相关月经过多长达12个月

Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas.
PubMed 文献 · Obstet Gynecol · 2020-01-01

Elaris UF-EXTEND是一项3期延伸研究,评估Elagolix 300mg每日两次联合雌二醇1mg/炔诺酮醋酸酯0.5mg反向添加疗法额外6个月(总计12个月)的安全性和疗效。218名受试者中87.9%达到主要终点,最常见不良事件为潮热,反向添加疗法可减轻单用Elagolix的低雌激素效应。

要点

  • Elagolix联合反向添加疗法治疗12个月持续减少月经过多。
  • 87.9%受试者达到主要终点(月经过少且较基线减少≥50%)。
  • 反向添加疗法可减轻单用Elagolix引起的骨密度下降。

核心结论

  • Elagolix联合反向添加疗法治疗长达12个月可提供持续的月经过多减少,且未发现新的或非预期安全性问题。

研究设计与样本

  • 3期延伸研究Elaris UF-EXTEND,纳入完成前两项3期研究中初始6个月相同治疗的女性,额外评估6个月(总计12个月)Elagolix 300mg每日两次联合雌二醇1mg和炔诺酮醋酸酯0.5mg每日一次。
  • 2016年9月至2019年3月共入组433名女性,其中218名接受长达12个月Elagolix联合反向添加疗法,平均年龄42.4±5.4岁,67.3%为黑人。

主要发现

  • 达到主要终点(最终月月经失血量<80mL且较基线减少≥50%)的女性比例为87.9%(95%CI [83.4-92.3])。
  • 治疗长达12个月最常见的不良事件为潮热(6.9%)、盗汗(3.2%)、头痛(5.5%)和恶心(4.1%)。
  • 从基线至延伸第6个月,Elagolix联合反向添加疗法组骨密度平均下降百分比显著低于单用Elagolix组,腰椎组间差异为-3.3(95%CI [-4.1至-2.5])。

临床怎么用

  • 对于子宫肌瘤相关月经过多的女性,可考虑Elagolix联合反向添加疗法治疗长达12个月以持续减少月经失血量。
  • 联合反向添加疗法有助于减轻Elagolix单用时的低雌激素效应(如骨密度下降)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the safety and efficacy of elagolix, an oral gonadotropin-releasing hormone antagonist, with hormonal add-back therapy for up to 12 months in women with heavy menstrual bleeding associated with uterine leiomyomas. METHODS: Elaris UF-EXTEND was a phase 3 extension study that evaluated an additional 6 months (up to 12 months total) of elagolix 300 mg twice daily with hormonal add-back therapy (estradiol 1 mg and norethindrone acetate 0.5 mg once daily) in women who completed an initial 6 months of the same treatment in one of two preceding phase 3 studies. The primary endpoint was the percentage of women with both less than 80 mL menstrual blood loss during final month and a 50% or greater reduction in menstrual blood loss from baseline to final month. Safety evaluations included adverse events and bone mineral density changes. The planned sample size of UF-EXTEND was based on estimated rollover and discontinuation rates in the two preceding studies. RESULTS: From September 2016 to March 2019, 433 women were enrolled in UF-EXTEND. Of these women, 218 received up to 12 months of elagolix with add-back therapy; the mean±SD age of this group was 42.4±5.4 years and 67.3% were black. The percentage of women who met the primary endpoint in this elagolix with add-back group was 87.9% (95% CI [83.4-92.3]). The most frequently reported adverse events with up to 12 months of elagolix plus add-back therapy were hot flush (6.9%), night sweats (3.2%), headache (5.5%), and nausea (4.1%). Mean percent decreases in bone mineral density from baseline to extension month 6 were significantly less with elagolix plus add-back therapy than with elagolix alone {between-group difference in lumbar spine: -3.3 (95% CI [-4.1 to -2.5])}. CONCLUSION: Up to 12 months of elagolix with add-back therapy provided sustained reduction in menstrual blood loss in women with uterine leiomyomas, with the addition of add-back therapy attenuating the hypoestrogenic effects of elagolix alone. No new or unexpected safety concerns were associated with an additional 6 months of elagolix with addback therapy. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02925494. FUNDING SOURCE: AbbVie Inc funded this study.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Simon JA, Al-Hendy A, Archer DF, et al. Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas. Obstet Gynecol. 2020. PMID: 32459423. doi:10.1097/AOG.0000000000003869

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。